Targeted Agent and Profiling Utilization Registry (TAPUR) Study

American Society of Clinical Oncology

Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Description

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Eligibility

Age range: 12+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * 12 years of age or older (\*Restrictions apply. Not all therapies are available for patients \<18) * Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated * Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria) * Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exc…

Interventions

Drug
Palbociclib
drug
Drug
Sunitinib
drug
Drug
Temsirolimus
drug
Drug
Trastuzumab and Pertuzumab
drug
Drug
Vemurafenib and Cobimetinib
drug
Drug
Regorafenib
drug
Drug
Olaparib
drug
Drug

Locations (174)

University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama
kunyuan@uabmc.edu 205-644-2584
Cancer Treatment Centers of America-Phoenix
Phoenix, Arizona
rfernandez@coh.org 623-207-3126
Sutter Auburn
Auburn, California
BabskiK@sutterhealth.org 916-878-4990
Sutter Alta Bates
Berkeley, California
Christopher.Tang@sutterhealth.org 510-204-3428
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California
tmata@theangelesclinic.org 310-231-2115
Kaiser Permanente - Oakland Medical Center
Oakland, California
desiree.goldstein@kp.org